HOWL - Werewolf Therapeutics GAAP EPS of -$0.39 beats by $0.16 revenue of $7.28M beats by $5.21M
2023-03-23 07:15:50 ET
- Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q4 GAAP EPS of -$0.39 beats by $0.16 .
- Revenue of $7.28M beats by $5.21M .
- As of December 31, 2022, cash and cash equivalents were $129.3 million, compared to $157.5 million as of December 31, 2021. After updating our expense forecasting, the Company now expects that its existing cash and cash equivalents, together with anticipated collaboration revenue, will be sufficient to fund its operational expenses and capital expenditure requirements through at least the fourth quarter of 2024.
For further details see:
Werewolf Therapeutics GAAP EPS of -$0.39 beats by $0.16, revenue of $7.28M beats by $5.21M